DeepMed Research

Chinese Academy of Medical Sciences Peking Union Medical College Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury

Phase 4

Not yet recruiting

Conditions: Hemodiafiltration With Ultrafiltrate Regeneration (HFR)
Multiple Myeloma
Acute Kidney Injury

Interventions: Procedure: HFR-SUPRA
Procedure: hemodialysis
Drug: Chemotherapy

First Posted Date: 2022-06-23

Last Posted Date: 2022-06-23

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 50

Registration Number: NCT05429515

Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy of Colorectal Cancer

Not Applicable

Recruiting

Conditions: Colon Cancer
Rectal Cancer
PTC
Chemotherapy Effect
Exon Mutation

Interventions: Drug: 5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil + formyltetrahydrofolate/Irinotecan + 5-fluorouracil + formyltetrahydrofolate/Cetuximab + 5-fluorouracil + formyltetrahydrofolate

First Posted Date: 2022-06-21

Last Posted Date: 2024-11-04

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 200

Registration Number: NCT05424692

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

Correlation Between Perioperative Autonomic Function and Post-induction Hypotension in Elderly Patients

Recruiting

Conditions: Intraoperative Hypotension

Interventions: Other: Perioperative autonomic function assessment

First Posted Date: 2022-06-21

Last Posted Date: 2024-04-19

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 180

Registration Number: NCT05425147

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, China

Evaluation of Prognostic Monitoring for Women Who Have Completed Standard Treatment for Ovarian Cancer

Recruiting

Conditions: Ovarian Cancer

First Posted Date: 2022-06-08

Last Posted Date: 2022-06-08

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 300

Registration Number: NCT05410015

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

New Serum Biomarkers for Monitoring Early Diagnosis of Ovarian Cancer Recurrence

Recruiting

Conditions: Ovarian Cancer

First Posted Date: 2022-06-08

Last Posted Date: 2022-06-08

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 1000

Registration Number: NCT05410028

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

Diagnosis of Metastatic Tumors on 68Ga-FAPI PET-CT and Radioligand Therapy With 177Lu-EB-FAPI

Early Phase 1

Conditions: 177Lu-EB-FAPI

Interventions: Drug: 68Ga-FAPI for PET / CT scan and 177Lu-EB-FAPI for therapy

First Posted Date: 2022-06-02

Last Posted Date: 2022-06-02

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 10

Registration Number: NCT05400967

Locations: 🇨🇳
Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, Beijing, China

Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL

Phase 2

Recruiting

Conditions: Primary Central Nervous System Lymphoma

Interventions: Drug: Orelabrutinib
Drug: Pomalidomide
Drug: Rituximab
Drug: Methotrexate

First Posted Date: 2022-05-25

Last Posted Date: 2022-05-25

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 50

Registration Number: NCT05390749

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳
Sanbo Brain Hospital Capital Medical University, Beijing, Beijing, China
🇨🇳
Beijing TianTan Hospital, Beijing, Beijing, China

A Phase II Trial to Explore Niraparib and Anlotinib Maintenance Retreatment in Platinum-Sensitive Recurrent Ovarian Cancer Patients Previously Treated With PARPi

Phase 2

Not yet recruiting

Conditions: Epithelial Ovarian Cancer

Interventions: Drug: Niraparib

First Posted Date: 2022-05-23

Last Posted Date: 2022-05-23

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 35

Registration Number: NCT05385068

A Multicentered Prospective Cohort Study of Chinese IBD Patients

Conditions: Crohn Disease
Ulcerative Colitis

Interventions: Drug: Infliximab
Drug: Vedolizumab
Drug: Ustekinumab
Drug: conventional treatment (glucocoticoid, immunosupressive drugs and/or mesalazine)

First Posted Date: 2022-05-23

Last Posted Date: 2022-05-23

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 200

Registration Number: NCT05386290

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

Neoadjuvant/Adjuvant Pembrolizumab Plus Chemotherapy

Phase 2

Active, not recruiting

Conditions: Non Small Cell Lung Cancer
Immune Checkpoint Inhibitor
Neoadjuvant Therapy

Interventions: Drug: Pembrolizumab

First Posted Date: 2022-05-20

Last Posted Date: 2024-04-23

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 80

Registration Number: NCT05383716

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy